Answers are grounded in this paper and cite their sources.
Objective Avacopan is an adjunctive therapy for severe active granulomatosis with polyangiitis and microscopic polyangiitis. We evaluated treatment patterns, glucocorticoid exposure and healthcare resource utilization (HCRU) among adults initiating avacopan, including a sub-cohort aged 65+. Methods This retrospective claims analysis utilized Medicare Fee-for-Service and MORE2 Registry® databases. Adults initiating avacopan with 12 months of continuous enrolment before and after index (first claim) were included. Among patients persistent (no ≥ 90-day gap) on avacopan, changes in prednisone-equivalent daily dose (PEDD) and HCRU were evaluated over 12 months in the primary cohort and a 65+ sub-cohort. Results Of 167 patients (median age 55 years), 53 (31.7%) were age ≥ 65 years. Among patients persistent on avacopan (n = 94), mean PEDD decreased from 12.6 mg/day during the 90 days pre-index to 5.1 mg/day at 12 months post-index in the primary cohort (n = 94), and from 15.1 to 6.9 mg/day in the 65+ sub-cohort (n = 25). In the primary cohort, the proportion of patients with emergency department visits decreased from 62.8% to 39.4%, and inpatient admissions from 55.3% to 21.3%. These reductions were also observed in the 65+ sub-cohort, where both emergency department visits and inpatient admissions declined from 60.0% and 68.0%, respectively, at baseline to below reporting thresholds at follow-up. Conclusions In this real-world analysis, avacopan use was associated with reduced glucocorticoid exposure and lower HCRU over 12 months among patients who remained on treatment. These trends were also observed in patients aged 65+. Longer-term comparator studies are needed.
No takes yet. Share an insight, caveat, or question.
Sattui et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: